Related Experiment Video
Updated: Jul 29, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability
R Ben-Ami1, G Sheinman, S Yedgar
1Department of Internal Medicine, Sourasky Medical Center, Tel-Aviv 64239, Israel. rbenami1@zahav.net.il
Thrombosis Research
|July 2, 2002
Summary
Thrombolytic therapy significantly reduces red blood cell (RBC) aggregation in acute myocardial infarction (AMI) patients. This effect, mediated by plasma changes like fibrinogen degradation, may improve blood flow and contribute to treatment efficacy.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Rheology
Background:
- Red blood cell (RBC) aggregation is implicated in coronary microcirculation occlusion during myocardial infarction (MI).
- Understanding the impact of treatments on RBC aggregation is crucial for improving patient outcomes in acute myocardial infarction (AMI).
Purpose of the Study:
- To investigate the effect of thrombolytic therapy on RBC aggregation in patients with AMI.
- To determine the mechanisms underlying changes in RBC aggregation following thrombolytic treatment.
Main Methods:
- Comparison of RBC aggregation in AMI patients receiving systemic thrombolysis versus those not treated.
- Measurement of plasma fibrinogen and D-dimer levels.
- Assessment of plasma-dependent RBC aggregation using a standardized dextran-500 solution.
Main Results:
- Thrombolytic therapy significantly reduced RBC aggregation in AMI patients.
- Patients treated with thrombolysis showed decreased plasma fibrinogen and increased plasma D-dimer levels.
- The reduction in RBC aggregation was dependent on plasma factors and not due to direct effects on RBCs.
Conclusions:
- Thrombolytic therapy exerts beneficial rheological effects by reducing RBC aggregation.
- Fibrinogen degradation and the generation of fibrinogen degradation products contribute to the anti-aggregatory effects of thrombolysis.
- These rheological changes may enhance the overall efficacy of thrombolytic treatment in AMI.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...